AAPG
Ascentage Pharma Group International Co., Ltd.
NASDAQ · Healthcare · Biotechnology · CN
$15.07
+11.75%Year over year
Reported trailing growth
- Revenue
- +62.1%
- EBITDA
- -26.0%
- EBIT
- -23.6%
- EPS
- -9.9%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +17.8%
- EBITDA
- +82.1%
- EPS
- +74.5%
Three-year CAGR
- Revenue
- +38.6%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026